AKT1 and neoplasm: In many experimental in vitro and/or in vivo models, XN was reported to inhibit tumour angiogenesis/invasion and tumour growth, mainly through the modulation of PI3K/AKT and mitogen-activated protein kinase (MAPK) signalling and their downstream substrates [20,62].